Angiostatin levels in diabetes mellitus patients receiving insulin treatment: associations with laboratory findings, comorbidities, and medications
Angiostatin levels in diabetes mellitus patients receiving insulin treatment: associations with laboratory findings, comorbidities, and medications
Background/aim: The clinical effect of angiostatin in diabetes mellitus (DM) patients receiving insulin is a meaningful gap in theliterature. In this study, we aimed to show the levels and the clinical significance of angiostatin in DM patients receiving insulin.Materials and methods: This is a case-control study. Serum angiostatin levels were determined by ELISA. A total of 83 people consistingof healthy subjects (n = 36) and patients with a diagnosis of DM receiving insulin therapy (n = 47) were included in this study.Results: The mean angiostatin levels of the DM group were significantly higher than those of the control group (86.0 ± 68.1 ng/mLand 58.0 ± 22.4 ng/mL, respectively; P = 0.011). Significantly lower angiostatin levels were determined in the DM patients receivingmetformin with respect to those not receiving metformin (97.2 ± 74.4 ng/mL and 49.3 ± 7.0 ng/mL, respectively; P = 0.021). Significantlyhigher levels of angiostatin were observed among the DM patients using a beta-blocker (BB) than the DM patients not using a BB (115.5± 78.71 ng/mL and 73.44 ± 60.08 ng/mL, respectively; p = 0.029).Conclusion: This is the first study evaluating and demonstrating the serum angiostatin levels in DM patients receiving insulin. Furtherstudies are required to understand the effect of angiostatin in diabetics and the effect of medications on angiogenesis in these patients.
___
- Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic
complications of diabetes mellitus: a mini review. Curr
Diabetes Rev 2017; 13: 3-10.
- IDF. Diabetes Atlas: Turkey Country Report. Brussels, Belgium:
IDF; 2017.
- Tatar M. Management of diabetes and diabetes policies in
Turkey. Global Health 2013; 9: 16.
- Praidou A, Androudi S, Brazitikos P, Karakiulakis G,
Papakonstantinou E, Dimitrakos S. Angiogenic growth factors
and their inhibitors in diabetic retinopathy. Curr Diabetes Rev
2010; 6: 304-312.
- Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P,
Soria C, Perricaudet M, Yeh P, Lu H. Angiostatin gene transfer;
inhibition of tumour growth in vivo by blockage of endothelial
cell proliferation associated with a mitosis arrest. P Natl Acad
Sci USA 1998; 95: 6367-6372.
- O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA,
Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin:
a novel angiogenesis inhibitor that mediates the suppression of
metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
- Chi SL, Pizzo SV. Angiostatin is directly cytotoxic to tumor
cells at low extracellular pH: a mechanism dependent on cell
surface-associated ATP synthase. Cancer Res 2006; 66: 875-
882.
- Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L,
Hubchak S, Schnaper HW, Pizzo SV. Angiogenesis binds ATP
synthase on the surface of human endothelial cells. P Natl Acad
Sci USA 1999; 96: 2811-2816
- Semeraro F, Cancarini A, dell’Omo R, Rezzola S, Romano MR,
Costagliola C. Diabetic retinopathy: vascular and inflammatory
disease. J Diabetes Res 2015; 2015: 16
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem
1972; 18: 499-502.
- Levey AS, Stevens LA. Estimating GFR using the CKD
Epidemiology Collaboration (CKD-EPI) creatinine equation:
more accurate GFR estimates, lower CKD prevalence
estimates, and better risk predictions. Am J Kidney Dis 2010;
55: 622-627.
- O’Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin
induces and sustains dormancy of human primary tumors in
mice. Nat Med 1996; 2: 689-692.
- Sodha NR, Clements RT, Boodhwani M, Xu SH, Laham RJ,
Bianchi C, Sellke FW. Endostatin and angiostatin are increased
in diabetic patients with coronary artery disease and associated
with impaired coronary collateral formation. Am J Physiol
Heart Circ Physiol 2009; 296: 428-434.
- Matyal R, Mahmood F, Robich M, Glazer H, Khabbaz K, Hess
P, Bianchi C, Hagberg R, Hu SX, Sellke FW. Chronic type II
diabetes mellitus leads to changes in neuropeptide Y receptor
expression and distribution in human myocardial tissue. Eur J
Pharmacol 2011; 665: 19-28.
- Chung AW, Hsiang YN, Matzke LA, McManus BM, van
Breemen C, Okon EB. Reduced expression of vascular
endothelial growth factor paralleled with the increased
angiostatin expression resulting from the upregulated activities
of matrix metalloproteinase-2 and -9 in human type 2 diabetic
arterial vasculature. Circ Res 2006; 99: 140-148.
- Bakhashab S, Ahmed FW, Schulten HJ, Bashir A, Karim
S, Al-Malki AL, Gari MA, Abuzenadah AM, Chaudhary
AG, Alqahtani MH et al. Metformin improves the
angiogenic potential of human CD34+ cells co-incident with
downregulating CXCL10 and TIMP1 gene expression and
increasing VEGFA under hyperglycemia and hypoxia within
a therapeutic window for myocardial infarction. Cardiovasc
Diabetol 2016; 15: 15-27.
- Bell DS. Advantages of a third-generation beta blocker
in patients with diabetes mellitus. Am J Cardiol 2004; 93:
49B-52B.
- Li D, Li P, Guo Z, Wang H, Pan W. Downregulation of miR382 by propranolol inhibits the progression of infantile
hemangioma via the PTEN-mediated AKT/mTOR pathway.
Int J Mol Med 2017; 39: 757-763.
- Childers WK, Hollenbeak CS, Cheriyath P. β-Blockers reduce
breast cancer recurrence and breast cancer death: a metaanalysis. Clin Breast Cancer 2015; 15: 426-431.
- Albini A, DeCensi A, Cavalli F, Costa A. Cancer prevention
and interception: a new era for chemopreventive approaches.
Clin Cancer Res 2016; 22: 4322-4327.
- Pettersson US, Henriksnäs J, Jansson L. Reversal of high
pancreatic islet and white adipose tissue blood flow in type 2
diabetic GK rats by administration of the beta3-adrenoceptor
inhibitor SR-59230A. Am J Physiol Endocrinol Metab 2009;
297: E490-494.
- Yamahara K, Min KD, Tomoike H, Kangawa K, Kitamura S,
Nagaya N. Pathological role of angiostatin in heart failure: an
endogenous inhibitor of mesenchymal stem-cell activation.
Heart 2009; 95: 283-289.
- Sima J, Zhang SX, Shao C, Fant J, Ma JX. The effect
of angiostatin on vascular leakage and VEGF expression in rat
retina. FEBS Lett 2004; 564: 19-23.
- Spranger J, Hammes HP, Preissner KT, Schatz H, Pfeiffer AF.
Release of the angiogenesis inhibitor angiostatin in patients
with proliferative diabetic retinopathy: association with retinal
photocoagulation. Diabetologia 2000; 43: 1404-1407.